What is uMed?
uMed operates at the intersection of healthcare technology and clinical research, providing a sophisticated, modular suite of decentralized study services. The platform is engineered to streamline patient recruitment and data collection, effectively facilitating faster and more representative evidence generation for pharmaceutical and clinical trial teams. By prioritizing security, compliance, and patient trust, uMed enables healthcare professionals to access diverse patient cohorts, thereby optimizing study workflows and enhancing the overall quality of medical research. Its market position is defined by its ability to integrate seamlessly into existing healthcare infrastructures while maintaining rigorous data standards.
How much funding has uMed raised?
uMed has raised a total of $12.4M across 1 funding round:
Other Financing Round
$12.4M
Other Financing Round (2023): $12.4M with participation from Delin Ventures, 11.2 Capital, Albion Ventures, and Playfair Capital
Key Investors in uMed
Delin Ventures
A mission-driven investor and company builder focused on transforming lives through innovations in life sciences and technology, providing operational expertise and long-term support.
11.2 Capital
A San Francisco-based venture capital firm specializing in emerging technologies, with a particular focus on artificial intelligence, cybersecurity, and robotics.
Albion Ventures
The technology investment arm of Albion Capital Group, focusing on high-growth B2B software and technology-enabled services with a strong track record in healthtech and deeptech.
What's next for uMed?
With this major enterprise-level funding, uMed is poised to scale its operations and expand its footprint within the global clinical trial market. The strategic deployment of this capital will likely focus on enhancing the platform's technological capabilities, deepening its integration with healthcare providers, and broadening its reach to support more complex, multi-site research initiatives. As the industry shifts toward decentralized models, uMed's focus on efficient, patient-centric data collection will be instrumental in maintaining its competitive advantage and driving long-term growth in the life sciences sector.
See full uMed company page
